- Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
This study looked at new treatments for HER2-positive breast cancer that had already been treated but still showed signs of cancer after surgery. Researchers wanted to see if adding certain drugs could prevent the cancer from coming back.
For: Breast CancerUnited States · Australia · Austria - RecruitingPHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
This study is for adults with a certain type of lung cancer (Stage II-IIIB non-small cell lung cancer) that has a specific genetic change (HER2 mutation) and has been fully removed by surgery. It compares a new daily tablet called zongertinib with standard treatments to see if it can stop the cancer from coming back.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
This study is testing new combinations of medicines for advanced liver cancer (hepatocellular carcinoma) that can't be cured with surgery. It compares different drug blends to a common treatment to see which works best and is safest.
For: Hepatocellular CarcinomaUnited States · Australia · Brazil - Active not recruitingPHASE1
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This study is testing two anti-cancer drugs, cabozantinib and atezolizumab, alone and together, for various advanced cancers. It aims to find a safe combination dose and see how well it works and any side effects.
For: Urothelial Carcinoma · Renal Cell Carcinoma · Non-Small Cell Lung CancerUnited States · Australia · Belgium - RecruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
This study is testing a new medicine, RO7566802, by itself and with another drug, atezolizumab, for people with advanced solid tumours. It aims to check if the treatment is safe, how it works in the body, and if it helps shrink tumours. It's an early-stage study.
For: Locally Advanced Solid Tumors · Recurrent Solid Tumors · Metastatic Solid TumorsUnited States · Australia · Canada - RecruitingPHASE2
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
This study looks at new ways to treat advanced cancers by matching specific drugs to changes found in a patient's tumour genes. It tests three different drugs – atezolizumab, futibatinib, and amivantamab – to see how well they shrink tumours in different groups of patients.
For: Advanced Solid TumorFrance · Germany · Italy - Active not recruitingPHASE1, PHASE2
A Trial of Ipatasertib in Combination With Atezolizumab
This study looks at combining two medicines, ipatasertib and atezolizumab, for advanced solid tumours and a type of brain tumour called glioblastoma. It aims to find the safest dose and see how well they work together. It's a early-stage study to understand more about these treatments.
For: Solid Tumor · Glioblastoma Multiforme · Prostate Cancer MetastaticUnited Kingdom - Ongoing, recruitingTherapeutic confirmatory (Phase III)
MOIO_Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with locally advanced or metastatic cancer in response after 6 months of standard IO
This study compares standard immunotherapy with a reduced dose for people whose cancer responded well after 6 months. It looks at how long they stay well and their quality of life. The aim is to see if a lower dose can be just as effective.
For: Only patients with oncologic locally advanced or metastatic tumour (lung cancer · renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination) · head and neck cancerFrance - RecruitingPHASE1
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
This study is testing a new drug, Ris-Rez, for people with advanced cancers. Researchers want to see if it's safe, how it works, and if it can help stop cancer growth, both alone and with other medicines.
For: NeoplasmsUnited States · Argentina · Canada - Active not recruitingPHASE1, PHASE2
WaKING: Wnt and checKpoint INhibition in Gastric Cancer
This study is for people with advanced stomach or gullet cancer that has spread, and who've already had chemotherapy. It's testing a new combination of medicines, DKN-01 and atezolizumab, to see if they are safe and can help shrink cancer.
For: Metastatic Esophageal Cancer · Metastatic Gastric CancerUnited Kingdom - RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
For: Small Cell Lung Cancer (SCLC) · Extensive-stage Small Cell Lung Cancer (ES-SCLC)United States · Argentina · Australia - RecruitingPHASE2
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
This study looks at new treatments for pancreatic cancer after surgery. It compares a new combination of drugs (Autogene Cevumeran, Atezolizumab, and mFOLFIRINOX) with a standard treatment (mFOLFIRINOX alone) to see which works best and is safest for patients with no remaining cancer after their operation.
For: Adenocarcinoma, Pancreatic DuctalUnited States · Belgium · Canada - RecruitingPHASE1, PHASE2
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
This study is looking at a new treatment called YL201 combined with an existing cancer drug, atezolizumab, for advanced small cell lung cancer. It aims to find a safe and effective dose of YL201 and see how well the combination works.
For: Thoracic Neoplasms, Lung Diseases, Small Cell Lung CarcinomaUnited States · Belgium · Italy - Active not recruitingPHASE1
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This study looks at a new drug called XL092 for advanced solid tumours like kidney, breast, prostate, or bowel cancer. Researchers are testing it alone and with other drugs (Atezolizumab, Avelumab) to see if it's safe, how it works, and if it can help slow down or shrink tumours.
For: Neoplasm Malignant · Renal Cell Carcinoma · Hormone Receptor Positive Breast CarcinomaUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
This study looks at a medicine called atezolizumab for people with a type of bladder cancer that has spread into the muscle. It checks if this medicine, given after surgery, can stop the cancer from coming back in those who show signs of tiny cancer cells in their blood.
For: Muscle-invasive Bladder CancerUnited States · Argentina · Belgium - Active not recruitingPHASE2
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC
This study is looking into a new treatment for an aggressive type of breast cancer called triple-negative breast cancer. It combines standard chemotherapy with two newer drugs, Atezolizumab and Ipatasertib, to see if this mix can fight the cancer better before surgery.
For: Triple Negative Breast CancerUnited Kingdom - RecruitingPHASE3
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
This study offers continued treatment to cancer patients already in certain Genentech/Roche studies. It's for those still benefiting from their current treatment and who can't get it elsewhere. The aim is to bridge care for these patients.
For: CancerBelgium · Canada · China - Active not recruitingPHASE3
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
This study is for people with cancer who are already receiving specific cancer treatments in another study. It allows them to continue their treatment if their original study ends and they can't get the medicine elsewhere. It's about safely extending access to these important cancer drugs.
For: CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
This study is for people with cancer that has spread, who are already benefiting from a specific medicine called trastuzumab emtansine (T-DM1) or other similar treatments in an earlier study. It allows them to keep receiving these important treatments for longer to see if they continue to help.
For: Neoplasm MetastasisUnited States · Australia · Belgium - Active not recruitingPHASE3
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
This study looks at treating a specific type of advanced lung cancer. It compares two treatments, atezolizumab alone or combined with lurbinectedin, after initial chemotherapy. The aim is to see which approach works best to keep the cancer stable.
For: Small-Cell Lung CancerUnited States · Belgium · Germany - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
This study compares a new combination medicine, BMS-986489 (BMS-986012 and Nivolumab), with a standard treatment (Atezolizumab), both given with chemotherapy. It's for people with a type of lung cancer called extensive-stage small cell lung cancer who are starting their first treatment.
For: Extensive-Stage Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
This study looks at new treatments for a type of oesophageal cancer that hasn't spread after initial therapy. It tests two new medicines, tiragolumab and atezolizumab, to see if they can help stop the cancer from coming back or getting worse.
For: Esophageal Squamous Cell CarcinomaUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.
For: Metastatic Breast CancerUnited States · Australia · France - RecruitingPHASE2, PHASE3
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
The DETERMINE trial is testing if existing cancer medicines can help people with rare cancers or common cancers with rare genetic changes. It includes adults, teenagers, and children. The goal is to find new ways to treat cancer and make these treatments available through the NHS.
For: Haematological Malignancy · Solid TumourUnited Kingdom - RecruitingPHASE3
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
This study is testing a new drug, Pumitamig, with chemotherapy for people with advanced small-cell lung cancer that hasn't been treated before. It aims to see if this new combination works better and is safe compared to a standard treatment.
For: Extensive-stage Small-cell Lung CancerUnited States · Australia · China - Active not recruiting
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This study looks at how a cancer drug called atezolizumab works in real patients. Researchers want to see its effects and safety under normal hospital care, for different types of cancer it's approved for.
For: Urothelial Carcinoma · Non-Small Cell Lung Cancer · Small Cell Lung CancerArgentina · Austria · Belgium - RecruitingPHASE1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
This study looks at new treatments for bowel cancer that has spread. We want to see if these targeted medicines or immunotherapy are safe and work well for people whose cancer has specific genetic features, which we call biomarkers.
For: Metastatic Colorectal CancerUnited States · Australia · Canada - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
This study looks at a new combination of drugs, cabozantinib and atezolizumab, for men with prostate cancer that has spread and is no longer responding to hormone therapy. It compares this new combination with standard hormone treatments to see if it works better.
For: Metastatic Prostate Cancer · Prostate AdenocarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
This study is testing new immune-based treatments for a type of bladder cancer that has spread. Researchers want to see if combinations of medicines like tobemstomig and tiragolumab are safe and work better than atezolizumab for people who can't have standard chemotherapy.
For: Urothelial CancerUnited States · Australia · Brazil - Active not recruitingPHASE2
A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung
This study is looking at a new treatment called Atezolizumab for a type of lung cancer called large-cell neuroendocrine carcinoma. It combines Atezolizumab with standard chemotherapy to see if it's safe and effective for people whose cancer has spread or can't be cured with other treatments.
For: Large Cell Neuroendocrine Carcinoma of the LungGermany - Active not recruiting
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
This study looks at how well different treatments work for adults with liver cancer that can't be removed by surgery. Researchers are collecting health information from medical records to find the best next steps for people who have already had a specific type of first-line therapy.
For: Unresectable Hepatocellular CarcinomaUnited States · Argentina · Brazil - Active not recruitingPHASE1
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
This study is looking into new ways to treat advanced cancers that have a specific genetic change called KRAS p.G12C. It's testing a drug called sotorasib, either by itself or with other treatments, to see how safe and effective they are for adults.
For: Advanced Solid Tumors · Kirsten Rat Sarcoma (KRAS) pG12C MutationUnited States · Australia · Austria - RecruitingPHASE3
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
This study compares two treatments for a type of liver cancer called hepatocellular carcinoma (HCC) in its intermediate stage. It looks at a combination of two drugs, atezolizumab and bevacizumab, against a standard treatment called TACE (Transarterial Chemoembolization), to see which works best and is safest.
For: Hepatocellular CarcinomaAustria · France · Germany - Active not recruitingPHASE3
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
This study is looking at new ways to treat advanced liver cancer that can't be removed by surgery. It combines existing medications with a new one to see if this mix works better and is safe. The aim is to find improved first-line treatments for this type of cancer.
For: Hepatocellular CarcinomaUnited States · Belgium · Brazil - Active not recruitingPHASE3
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
This study is looking at a new treatment for liver cancer to stop it coming back after surgery or other procedures. It compares two drugs, atezolizumab and bevacizumab, with regular check-ups to see which is better at preventing the cancer from returning.
For: Carcinoma, HepatocellularUnited States · Australia · Austria - Active not recruitingPHASE2
NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing
This study looks at combining chemotherapy with two new drugs, tiragolumab and atezolizumab, before and after surgery for certain lung cancers. It aims to see if this combination is safe and effective for patients with non-small cell lung cancer.
For: Non-small Cell Lung CancerGermany - Active not recruitingPHASE1, PHASE2
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
This study is testing a new combination treatment for a type of lung cancer called Extensive Stage Small Cell Lung Cancer (ES-SCLC). It aims to find a safe dose and see if this new combination works better than current treatments for people newly diagnosed with this aggressive cancer.
For: Extensive Stage Small Cell Lung CancerUnited States · Austria · Canada - Active not recruitingPHASE3
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
This study looked at new ways to treat a type of lung cancer called extensive-stage small cell lung cancer (ES-SCLC). It compared a combination of medicines with standard chemotherapy to see if it could help people live longer. The study was changed partway through, so the focus shifted.
For: Small Cell Lung CarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE1
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
This study looks at a new drug, inavolisib, alone or with another drug, atezolizumab, for cancers with a specific change (PIK3CA mutation). It aims to see if they are safe and work well, especially for certain head and neck cancers.
For: PIK3CA-Mutated CancersUnited States · Canada · South Korea - RecruitingPHASE2, PHASE3
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
This study is looking into new treatments for advanced liver cancer (hepatocellular carcinoma). It compares new drug combinations, livmoniplimab with budigalimab, against existing treatments to find the best dose and see how well they work and what side effects they might have.
For: Hepatocellular CarcinomaUnited States · France · Italy - Active not recruitingPHASE3
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
This study compares a new treatment, Atezolizumab, to standard care for patients with early-stage lung cancer after surgery and chemotherapy. It aims to see if Atezolizumab can prevent the cancer from returning and help people live longer.
For: Non-Small Cell Lung CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
This study looks at new drug combinations for advanced liver cancer that has already been treated. It compares atezolizumab with lenvatinib or sorafenib against lenvatinib or sorafenib alone, to see if the combinations work better and are safe.
For: Unresectable Hepatocellular CarcinomaAustria · Belgium · Brazil - Active not recruitingPHASE1
Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC
This study is looking into a new treatment for advanced liver cancer (hepatocellular carcinoma) that can't be removed by surgery. It combines a new drug, NP137, with two existing drugs, Atezolizumab and Bevacizumab, to see if it's safe and helps people live longer and respond better to treatment.
For: Hepatocellular CarcinomaFrance - Active not recruitingPHASE1, PHASE2
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This study looks at new drug combinations for adults with a type of blood cancer called Non-Hodgkin's Lymphoma that has come back or not responded to previous treatments. It aims to find the safest dose and see how well these new treatments work.
For: Non-Hodgkins LymphomaBelgium · Denmark · Israel - Active not recruitingPHASE2, PHASE3
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations for advanced non-small cell lung cancer. It aims to find out how safe and effective these treatments are for people whose cancer has specific genetic changes, using blood tests to identify these changes.
For: Non-Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
This study looks at a new treatment for advanced lung cancer in people aged 70-89. It combines standard chemotherapy (Carboplatin, Paclitaxel) with an immunotherapy drug called Atezolizumab, to see if it's effective and well-tolerated in this age group.
For: Non Small Cell Lung Cancer MetastaticFrance - RecruitingPHASE2
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
This study looks at a medicine called atezolizumab for different cancers. We want to see if a special test of your cancer cells can predict if the medicine will work well for you. This helps us learn more about tailoring treatments.
For: Breast Cancer · Lung Cancer · Gastrointestinal CancerCanada - RecruitingPHASE2
Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer
This study looks at a drug called atezolizumab for certain urinary system cancers before surgery. It aims to see if the drug can shrink tumours, making surgery more effective. The drug works by helping your body's immune system fight the cancer.
For: Urogenital CancerUnited Kingdom - Active not recruitingPHASE2
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
This study is testing a new medicine, Atezolizumab, for children and young people aged 2 to 17 with certain types of rare cancers: clear cell sarcoma or chondrosarcoma. It aims to see how well the medicine helps the body's immune system fight the cancer.
For: Central Chondrosarcoma, Grade 2 · Central Chondrosarcoma, Grade 3 · Dedifferentiated ChondrosarcomaUnited States · Canada - Active not recruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This study is testing a new medicine, GDC-6036, for people with advanced cancers that have a specific genetic change called KRAS G12C. It will look at how safe the medicine is and if it helps shrink tumors, sometimes combined with other treatments.
For: Non-Small Cell Lung Cancer · Colorectal Cancer · Advanced Solid TumorsUnited States · Australia · Belgium